Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
LSD
amphetamine Hallucinogen |
| gptkbp:actsOn |
5-HT2A receptor agonist
|
| gptkbp:CASNumber |
934914-32-8
|
| gptkbp:chemicalFormula |
C18H22BrNO3
|
| gptkbp:developedBy |
gptkb:Ralf_Heim
|
| gptkbp:hasStreet |
N-Bomb
BOMe-2C-B NBOMe-B |
| https://www.w3.org/2000/01/rdf-schema#label |
25B-NBOMe
|
| gptkbp:IUPACName |
2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
|
| gptkbp:legalStatus |
gptkb:Schedule_I_(United_States)
gptkb:Class_A_(United_Kingdom) illegal (Sweden) |
| gptkbp:molecularWeight |
380.28 g/mol
|
| gptkbp:relatedTo |
gptkb:25C-NBOMe
gptkb:25I-NBOMe |
| gptkbp:riskFactor |
death
overdose seizures hallucinations vasoconstriction |
| gptkbp:routeOfAdministration |
insufflation
sublingual buccal |
| gptkbp:toxicity |
high
|
| gptkbp:usedFor |
recreational drug
|
| gptkbp:year_of_first_synthesis |
2004
|
| gptkbp:bfsParent |
gptkb:NBOMe_series
|
| gptkbp:bfsLayer |
7
|